The Pharma is a global pharmaceutical company, with headquarters in Japan and USA offices on the East Coast. The Pharma focuses on developing and marketing products in the pharmaceutical and nutraceutical businesses. Currently, the Pharma is actively seeking novel and innovative therapeutic opportunities for in-licensing in CNS and nephrology. In addition, the firm manages an early-stage investment fund (currently $30M) that actively invests in global early-stage opportunities that fit the firm’s areas of interest.
The Pharma is interested in innovative therapeutics that address areas of significant unmet need in CNS and renal diseases. The Pharma is a global leader in CNS, both neurology and psychiatry, opportunistic to all types of indications, both symptomatic and disease-modifying. In nephrology, the firm is particularly interested in novel mechanism addressing both acute and chronic kidney diseases of tubular and glomerular origin, as well as associated inflammatory and fibrotic mechanisms. The firm will consider both clinical and pre-clinical compounds with compelling biological valid proof-of-concept.
The Pharma has no specific management team requirements and will work with all types of companies with an innovative product or pipeline. The firm aims to obtain global commercial rights as a preferential end-goal.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply